Search the Newsreel

Pulmatrix, Inc. Q2 2026: Net loss $1.05M, EPS $(0.29) — 10-Q Summary

Pulmatrix, Inc. reported a net loss of $1.05M for Q2 2026, an improvement from $1.55M in Q2 2025, with diluted EPS of $(0.29). The company is transitioning its operating model, pausing internal clinical development, and seeking to monetize its programs (PUR3100, PUR1800, PUR1900) through …

Pulmatrix posts Q2 2026 net loss $1.04M, cash $2.2M; files Form S-4 for Eos merger

Pulmatrix reported a Q2 2026 net loss of $1.04 million and held $2.2 million in cash and cash equivalents. The company has filed a Form S-4 in relation to its proposed merger with Eos SENOLYTIX, which is expected to close in Q3 2026. Clinical …

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

Pulmatrix, Inc. announced its second-quarter 2026 financial results and provided an update on its proposed merger with Eos SENOLYTIX, which is expected to close in Q3 2026. The company is focusing on advancing the merger while also seeking to out-license or monetize its clinical …

Form 8K Pulmatrix Inc For: 13 August By Investing.com

This article announces that Pulmatrix Inc. filed a Form 8K on August 13. The brief piece from Investing.com indicates that the filing pertains to the company PULM, which saw a -5.06% change. No further details about the content of the Form 8K are provided.

LeMaitre Vascular: 31% Drawdown On $0.02 Guidance Cut (NASDAQ:LMAT)

Pulmatrix Says $2.2M Cash Could Fund Operations Through Eos Merger

The Top 5 Analyst Questions From LeMaitre’s Q2 Earnings Call

The Top 5 Analyst Questions From LeMaitre's Q2 Earnings Call LeMaitre's second quarter was marked by strong organic revenue gains, led by robust growth in its Artegraft line and continued expansion across Europe and Asia. However, the quarter fell short of Wall Street's revenue …

Q2 Earnings Highs And Lows: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Q2 Earnings Highs And Lows: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks Let's dig into the relative performance of LeMaitre (NASDAQ:LMAT) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - specialty earnings …

LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Navigating a 39% Potential Upside in the Healthcare Sector

LeMaitre Vascular, Inc. (LMAT), a healthcare sector player specializing in vascular surgery medical devices, shows a potential upside of 39.33% with an average target price of $113.13. Despite trading below its 50-day and 200-day moving averages, the company exhibits strong operational efficiency, a healthy …

LeMaitre Vascular (LMAT) Has A Fresh Update, So Why Is It Drawing Attention?

LeMaitre Vascular (LMAT) recently released strong second-quarter 2026 results with increased sales and net income, alongside updated guidance and a reaffirmed cash dividend. Despite positive long-term shareholder returns, recent share price performance has been weak. The stock is considered undervalued by analysts, trading 31.4% …

Quantinno Capital Management LP Buys 18,204 Shares of LeMaitre Vascular, Inc. $LMAT

Quantinno Capital Management LP significantly increased its stake in LeMaitre Vascular, Inc. by 357.4%, acquiring 18,204 additional shares. This brings their total holding to 23,298 shares, valued at approximately $2.54 million. The news comes as LeMaitre Vascular faces mixed analyst sentiment due to missing …

LeMaitre Vascular, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

LeMaitre Vascular, Inc. recently missed its statutory earnings estimates, causing its shares to drop by 21%. Despite the earnings miss, revenue remained in line with predictions, and analysts have largely maintained their price targets, though they slightly downgraded next year's EPS forecasts. The company …

Pulmatrix Inc (PULM) Stock News Today

Pulmatrix Inc (PULM) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Pulmatrix Inc (PULM), noting that no earnings forecast score is currently available for the company. It mentions the Biotechnology & Medical Research industry average score and includes a section on analyst ratings, though no specific ratings are …

31% Undervalued? LeMaitre Vascular (LMAT) After Earnings Guidance And Dividend Update

LeMaitre Vascular (LMAT) reported strong Q2 2026 results with increased sales and net income, affirming its quarterly dividend. While analysts view the stock as 31.4% undervalued with a fair value of $118.75 due to a strong product pipeline and pricing power, Simply Wall St's …

LeMaitre management to meet investors at virtual Aug. 11 event

LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that its management will participate in investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026. The event will be held in a virtual format. The company specializes in devices …

LeMaitre Vascular To Go Ex-Dividend On August 20th, 2026 With 0.25 USD Dividend Per Share

LeMaitre Vascular is scheduled to go ex-dividend on August 20th, 2026. The company will be distributing a dividend of $0.25 per share to its shareholders. Investors wishing to receive this dividend should ensure they own shares before the ex-dividend date.

LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

LeMaitre Vascular, Inc. announced its participation in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 11, 2026, where management will hold investor meetings. The company, a provider of devices for peripheral vascular disease, aims to connect with investors regarding its …

LeMaitre Vascular (LMAT) Hit by Profit Taking

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 …

LeMaitre Vascular (LMAT) Stock Price Hit By Revenue Guidance Cut

LeMaitre Vascular (NASDAQ:LMAT) Sets New 1-Year Low on Analyst Downgrade

LeMaitre Vascular (NASDAQ:LMAT) shares hit a new 52-week low after Wells Fargo downgraded its price target and maintained an equal-weight rating, amidst a broader shift in analyst sentiment to "Hold." The company's Q2 revenue and EPS, despite year-over-year growth, missed analyst expectations, leading to …

LeMaitre Vascular, Inc. Stock 12‑Month Price Target Cut to $116.25, Implies 10% Upside

LeMaitre Vascular, Inc.'s average 12-month price target has been lowered from $118.75 to $116.25 by 8 analysts, suggesting a 10% upside from its Aug. 4 closing price. The consensus rating remains a "Buy" from 9 analysts, with 5 recommending Buy and 4 recommending Hold.

LeMaitre Vascular stock hits 52-week low at 79.38 USD

LeMaitre Vascular (LMAT) stock recently hit a 52-week low at $79.38, despite having a strong 1-year return of nearly 25% and being up over 31% year-to-date. The medical device maker is trading below its Fair Value estimate, with analysts setting price targets between $100 …

LeMaitre Vascular Down Over 22%, On Track for Largest Percent Decrease Since October 2008 -- Data Talk

LeMaitre Vascular Inc. (LMAT) experienced a significant drop of over 22%, trading at $82.06, which would mark its lowest close since January 2026. This decline puts the company on track for its largest percentage decrease since October 2008. The stock is down 30.1% from …

LeMaitre Vascular (NASDAQ:LMAT) Price Target Cut to $94.00 by Analysts at Wells Fargo & Company

Wells Fargo & Company analysts have cut their price target for LeMaitre Vascular (NASDAQ:LMAT) to $94.00 from $104.00, maintaining an "equal weight" rating. This adjustment follows the company's recent earnings report where Q2 EPS of $0.74 missed the consensus estimate of $0.81, and revenue …

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Announces $0.25 Quarterly Dividend

LeMaitre Vascular, Inc. (NASDAQ:LMAT) declared a quarterly dividend of $0.25 per share, payable on September 3rd to shareholders of record on August 20th. This announcement comes despite the company missing analyst expectations for both Q2 revenue and EPS, and subsequently lowering its full-year 2026 …

LeMaitre Vascular (NASDAQ:LMAT) Stock Rating Lowered by Barrington Research

Royal Bank of Canada Sells 18,448 Shares of LeMaitre Vascular, Inc. $LMAT

Royal Bank of Canada reduced its stake in LeMaitre Vascular, Inc. (LMAT) by 6.3% in the first quarter, selling 18,448 shares but still retaining a significant holding of 272,654 shares valued at $29.8 million. This comes as LeMaitre Vascular reported Q2 earnings that missed …

LeMaitre Vascular Inc (LMAT) (Q2 2026) Earnings Call Highlights: Strong EPS Growth and ...

LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Lag Estimates

LeMaitre Vascular (LMAT) reported Q2 earnings of $0.74 per share, falling short of the Zacks Consensus Estimate of $0.81, though it was an increase from $0.60 a year ago. The company's revenues of $70.38 million also missed expectations, despite being higher than the $64.23 …

LeMaitre Vascular (NASDAQ:LMAT) Issues Q3 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) has lowered its third-quarter 2026 earnings guidance, projecting EPS of $0.660–$0.710 and revenue of $66.3–$68.3 million, both below analyst consensus. The company also updated its full-year 2026 EPS guidance to $2.840–$2.940. Despite the lowered outlook, analyst sentiment remains "Moderate Buy" with …

How Investors Are Reacting To LeMaitre Vascular (LMAT) Slower Projected Revenue Growth And Mixed Earnings Track Record

Earnings call transcript: LeMaitre Vascular slips on Q2 2026 miss, cuts outlook

LeMaitre Vascular reported a Q2 2026 earnings and revenue miss, leading to a significant after-hours stock drop. Despite strong year-over-year growth and margin expansion, the company cut its full-year organic revenue growth outlook due to foreign exchange pressures, Middle East shipping delays, and cardiac …